First drug approved for most common inherited kidney disease

The U.S. Food and Drug Administration has approved the first drug to slow kidney decline in patients with the most common inherited kidney disease.

Jynarque (jihn-AR'-kew), from Japan's Otsuka Pharmaceutical, was approved Tuesday for autosomal dominant polycystic .

The progressive genetic disorder is the fourth-leading cause of . It causes fluid-filled cysts to develop in and damage kidneys.

The FDA rejected it in 2013 but approved it after the drugmaker did an additional study. That one-year study, involving 1,370 patients with advanced disease, found the drug on average slowed kidney function decline about 35 percent more than dummy pills.

Otsuka says the drug, also known as tolvaptan, will cost $13,041 per month without insurance.

Jynarque can cause serious, even fatal liver injury, excessive urination and other side effects.


Explore further

New findings on tolvaptan as autosomal dominant polycystic kidney disease treatment

© 2018 The Associated Press. All rights reserved.

Citation: First drug approved for most common inherited kidney disease (2018, April 24) retrieved 20 September 2019 from https://medicalxpress.com/news/2018-04-drug-common-inherited-kidney-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more